Literature DB >> 11107140

Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.

X X Tang1, H Zhao, M E Robinson, A Cnaan, W London, S L Cohn, N K Cheung, G M Brodeur, A E Evans, N Ikegaki.   

Abstract

BACKGROUND: EPH family receptor tyrosine kinases and their ligand ephrins play pivotal roles in development. High-level expression of transcripts encoding EPHB6 receptors (EPHB6), its ligands ephrin-B2 and ephrin-B3 (EFNB2, EFNB3) is predictive of favorable disease outcome of neuroblastoma (NB). When combined with TrkA expression, the expression of EPHB6, EFNB2, or EFNB3 predicts more accurately the disease outcome than each of the four variables alone. PROCEDURE: Cox regression and Kaplan-Meier analyses were used to assess the prognostic significance of EPHB6, EFNB2, EFNB3, and TrkA expressions in NB without MYCN amplification.
RESULTS: High-level expression of EFNB3 or TrkA predicted favorable NB outcome of NB without MYCN amplification (p < 0.03). As found in the general NB population, EPHB6, EFNB2, or EFNB3 expression in combination with TrkA expression was significantly predictive of the disease outcome of normal MYCN NB (p < 0.01).
CONCLUSIONS: EPHB6, EFNB2, and EFNB3 expressions may permit further refinement of the prognostic stratification of NB into favorable and unfavorable groups. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107140     DOI: 10.1002/1096-911x(20001201)35:6<656::aid-mpo37>3.0.co;2-a

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

1.  Identification of genetic risk associated with prostate cancer using ancestry informative markers.

Authors:  L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-17       Impact factor: 5.554

2.  EPH-EPHRIN in human gastrointestinal cancers.

Authors:  Haruhiko Sugimura; Jian-Dong Wang; Hiroki Mori; Masaru Tsuboi; Kiyoko Nagura; Hisaki Igarashi; Hong Tao; Ritsuko Nakamura; Hiroko Natsume; Tomoaki Kahyo; Kazuya Shinmura; Hiroyuki Konno; Yasushi Hamaya; Shigeru Kanaoka; Hideki Kataoka; Xiao-Jun Zhou
Journal:  World J Gastrointest Oncol       Date:  2010-12-15

Review 3.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

4.  High expression of EphB6 protein in tongue squamous cell carcinoma is associated with a poor outcome.

Authors:  Yingchun Dong; Jicheng Pan; Yanhong Ni; Xiaofeng Huang; Xiao Chen; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.

Authors:  James M Paul; Behzad Toosi; Frederick S Vizeacoumar; Kalpana Kalyanasundaram Bhanumathy; Yue Li; Courtney Gerger; Amr El Zawily; Tanya Freywald; Deborah H Anderson; Darrell Mousseau; Rani Kanthan; Zhaolei Zhang; Franco J Vizeacoumar; Andrew Freywald
Journal:  Oncotarget       Date:  2016-08-02

6.  EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Authors:  Behzad M Toosi; Amr El Zawily; Luke Truitt; Matthew Shannon; Odette Allonby; Mohan Babu; John DeCoteau; Darrell Mousseau; Mohsin Ali; Tanya Freywald; Amanda Gall; Frederick S Vizeacoumar; Morgan W Kirzinger; C Ronald Geyer; Deborah H Anderson; TaeHyung Kim; Alana L Welm; Peter Siegel; Franco J Vizeacoumar; Anthony Kusalik; Andrew Freywald
Journal:  Oncogene       Date:  2018-04-27       Impact factor: 9.867

7.  Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas.

Authors:  Zhichao Liu; Changchun Li
Journal:  J Oncol       Date:  2021-09-13       Impact factor: 4.375

8.  Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer.

Authors:  Etmar Bulk; Jun Yu; Antje Hascher; Steffen Koschmieder; Rainer Wiewrodt; Utz Krug; Bernd Timmermann; Alessandro Marra; Ludger Hillejan; Karsten Wiebe; Wolfgang E Berdel; Albrecht Schwab; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.